Our multidisciplinary team follows a large number of patients from the province and regional surroundings. In addition, we coordinate the Emilia Romagna population-based registry for ALS and thereby contribute to epidemiological research. We collaborate with national and international institutes to develop multicenter projects for clinical research. Besides participating in several clinical trials, we currently lead three Italian ‘randomized controlled trials’ studying candidate therapies for ALS. We manage a neurobiobank, which allows the storage of high-quality and thoroughly characterized patient samples together with a fully equipped laboratory for molecular biology, cell biology and genetics. We are part of the ITALSGEN Consortium for genetic research and we actively collaborate with the University of Modena on translational ALS projects and epidemiological studies. The core of our research team is represented by 4 MND consultants, a data manager, 2 research nurses, a biologist. The local Statistics Unit grants full support for our data analysis. Other facilities include a fully equipped clinical neurophysiology laboratory, a neuropsychology unit and 3T GE system MRI scanner.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).